Abstract
Herbal components have been explored as a potential alternative treatment for neurological disorders due to the limitations and potential adverse effects of conventional treatments. Alzheimer’s disease is the most prevalent progressive human neurodegenerative condition marked by senile plaques and neurofibrillary tangles as well as gradual cognitive impairments; the most prominent of which is memory loss. Different therapy techniques incorporating synthetic and herbal approaches are being employed against AD based on the knowledge of the disease process. Commonly used herbal components, such as Ginkgo biloba, Bacopa monnieri, Withania somnifera, Passiflora incarnata, Rhodiola rosea, and Curcuma longa, have been shown to improve symptoms and cognitive function in individuals with neurological disorders, such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. However, more research is needed to fully understand the efficacy, safety, and potential interactions with other medications. By continuously exploring and researching the use of herbal components for neurological disorders, we can develop a better understanding of their potential to offer safe and effective alternative treatments.
Graphical Abstract
[1]
Ndam Ngoungoure VL, Mfotie Njoya E, Ngamli Fewou S, Fils Ella A, McGaw LJ, Moundipa PF. Acetylcholinesterase inhibitory, anti-inflammatory and antioxidant properties of some Cameroonian medicinal plants used to treat some neurological disorders. Investig Med Chem Pharmacol 2019; 2(2): 1-13.
[http://dx.doi.org/10.31183/imcp.2019.00033]
[http://dx.doi.org/10.31183/imcp.2019.00033]
[2]
Liu Q, Zhang A, Wang L, et al. High-throughput chinmedomics-based prediction of effective components and targets from herbal medicine AS1350. Sci Rep 2016; 6(1): 38437.
[http://dx.doi.org/10.1038/srep38437] [PMID: 27910928]
[http://dx.doi.org/10.1038/srep38437] [PMID: 27910928]
[3]
Ayeni EA, Gong Y, Yuan H, Hu Y, Bai X, Liao X. Medicinal plants for anti-neurodegenerative diseases in west africa. J Ethnopharmacol 2022; 285: 114468.
[http://dx.doi.org/10.1016/j.jep.2021.114468] [PMID: 34390796]
[http://dx.doi.org/10.1016/j.jep.2021.114468] [PMID: 34390796]
[4]
Singh SK, Srivastav S, Castellani RJ, Plascencia-Villa G, Perry G. Neuroprotective and Antioxidant Effect of Ginkgo biloba Extract against AD and other neurological disorders. Neurotherapeutics 2019; 16(3): 666-74.
[http://dx.doi.org/10.1007/s13311-019-00767-8] [PMID: 31376068]
[http://dx.doi.org/10.1007/s13311-019-00767-8] [PMID: 31376068]
[5]
Mohseni M, Sahebkar A, Askari G, Johnston TP, Alikiaii B, Bagherniya M. The clinical use of curcumin on neurological disorders: An updated systematic review of clinical trials. Phyther Res 2021; 35(12): 6862-82.
[http://dx.doi.org/10.1002/ptr.7273]
[http://dx.doi.org/10.1002/ptr.7273]
[6]
Banerjee S, Anand U, Ghosh S, Ray D, Ray P, Nandy S, et al. Bacosides from Bacopa monnieri extract: An overview of the effects on neurological disorders. Phyther Res 2021; 35(10): 5668-9.
[http://dx.doi.org/10.1002/ptr.7203]
[http://dx.doi.org/10.1002/ptr.7203]
[7]
de Caires S, Steenkamp V. Use of Yokukansan (TJ-54) in the treatment of neurological disorders: A review. Phyther Res 2010; 24(9): 1265-70.
[http://dx.doi.org/10.1002/ptr.3146]
[http://dx.doi.org/10.1002/ptr.3146]
[8]
Wang ZJ, Heinbockel T. Essential oils and their constituents targeting the GABAergic system and sodium channels as treatment of neurological diseases. Molecules 2018; 23(5): 1061.
[http://dx.doi.org/10.3390/molecules23051061] [PMID: 29724056]
[http://dx.doi.org/10.3390/molecules23051061] [PMID: 29724056]
[9]
Iriti M, Vitalini S, Fico G, Faoro F. Neuroprotective herbs and foods from different traditional medicines and diets. Molecules 2010; 15(5): 3517-55.
[http://dx.doi.org/10.3390/molecules15053517] [PMID: 20657497]
[http://dx.doi.org/10.3390/molecules15053517] [PMID: 20657497]
[10]
Ren ZL, Zuo PP. Neural regeneration: Role of traditional Chinese medicine in neurological diseases treatment. J Pharmacol Sci 2012; 120(3): 139-45.
[http://dx.doi.org/10.1254/jphs.12R06CP] [PMID: 23099323]
[http://dx.doi.org/10.1254/jphs.12R06CP] [PMID: 23099323]
[11]
Diamond BJ, Shiflett SC, Feiwel N, et al. Ginkgo biloba extract: Mechanisms and clinical indications. Arch Phys Med Rehabil 2000; 81(5): 668-78.
[http://dx.doi.org/10.1016/S0003-9993(00)90052-2] [PMID: 10807109]
[http://dx.doi.org/10.1016/S0003-9993(00)90052-2] [PMID: 10807109]
[12]
Ramassamy C. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: A review of their intracellular targets. Eur J Pharmacol 2006; 545(1): 51-64.
[http://dx.doi.org/10.1016/j.ejphar.2006.06.025] [PMID: 16904103]
[http://dx.doi.org/10.1016/j.ejphar.2006.06.025] [PMID: 16904103]
[13]
Kleijnen J, Knipschild P. Ginkgo biloba for cerebral insufficiency. Br J Clin Pharmacol 1992; 34(4): 352-8.
[http://dx.doi.org/10.1111/j.1365-2125.1992.tb05642.x] [PMID: 1457269]
[http://dx.doi.org/10.1111/j.1365-2125.1992.tb05642.x] [PMID: 1457269]
[14]
Mahadevan S, Park Y. Multifaceted therapeutic benefits of Ginkgo biloba L.: Chemistry, efficacy, safety, and uses. J Food Sci 2008; 73(1): R14-9.
[http://dx.doi.org/10.1111/j.1750-3841.2007.00597.x] [PMID: 18211362]
[http://dx.doi.org/10.1111/j.1750-3841.2007.00597.x] [PMID: 18211362]
[15]
Luo Y, Smith JV. Studies on molecular mechanisms of Ginkgo biloba extract. Appl Microbiol Biotechnol 2004; 64(4): 465-72.
[http://dx.doi.org/10.1007/s00253-003-1527-9] [PMID: 14740187]
[http://dx.doi.org/10.1007/s00253-003-1527-9] [PMID: 14740187]
[16]
Russo A, Borrelli F. Bacopa monniera, a reputed nootropic plant: An overview. Phytomedicine 2005; 12(4): 305-17.
[http://dx.doi.org/10.1016/j.phymed.2003.12.008] [PMID: 15898709]
[http://dx.doi.org/10.1016/j.phymed.2003.12.008] [PMID: 15898709]
[17]
Singh HK, Rastogi RP, Srimal RC, Dhawan BN. Effect of bacosides A and B on avoidance responses in rats. Phyther Res 1988; 2(2): 70-5.
[http://dx.doi.org/10.1002/ptr.2650020205]
[http://dx.doi.org/10.1002/ptr.2650020205]
[18]
Morgan A, Stevens J. Does Bacopa monnieri improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trial. J Altern Complement Med 2010; 16(7): 753-9.
[http://dx.doi.org/10.1089/acm.2009.0342] [PMID: 20590480]
[http://dx.doi.org/10.1089/acm.2009.0342] [PMID: 20590480]
[19]
Aguiar S, Borowski T. Neuropharmacological review of the nootropic herb Bacopa monnieri. Rejuvenation Res 2013; 16(4): 313-26.
[http://dx.doi.org/10.1089/rej.2013.1431] [PMID: 23772955]
[http://dx.doi.org/10.1089/rej.2013.1431] [PMID: 23772955]
[20]
Sandhir R, Sood A. Neuroprotective potential of Withania somnifera (Ashwagandha). Science of Ashwagandha: Preventive and therapeutic potentials. Cham: Springer International Publishing 2017; pp. 373-87.
[http://dx.doi.org/10.1007/978-3-319-59192-6_18]
[http://dx.doi.org/10.1007/978-3-319-59192-6_18]
[21]
Kuboyama T, Tohda C, Komatsu K. Withanoside IV and its active metabolite, sominone, attenuate Aβ(25-35)-induced neurodegeneration. Eur J Neurosci 2006; 23(6): 1417-26.
[http://dx.doi.org/10.1111/j.1460-9568.2006.04664.x] [PMID: 16553605]
[http://dx.doi.org/10.1111/j.1460-9568.2006.04664.x] [PMID: 16553605]
[22]
Kaur T, Singh H, Mishra R, et al. Withania somnifera as a potential anxiolytic and immunomodulatory agent in acute sleep deprived female Wistar rats. Mol Cell Biochem 2017; 427(1-2): 91-101.
[http://dx.doi.org/10.1007/s11010-016-2900-1] [PMID: 28004351]
[http://dx.doi.org/10.1007/s11010-016-2900-1] [PMID: 28004351]
[23]
Ahmad MK, Mahdi AA, Shukla KK, et al. Withania somnifera improves semen quality by regulating reproductive hormone levels and oxidative stress in seminal plasma of infertile males. Fertil Steril 2010; 94(3): 989-96.
[http://dx.doi.org/10.1016/j.fertnstert.2009.04.046] [PMID: 19501822]
[http://dx.doi.org/10.1016/j.fertnstert.2009.04.046] [PMID: 19501822]
[24]
Pratte MA, Nanavati KB, Young V, Morley CP. An alternative treatment for anxiety: A systematic review of human trial results reported for the Ayurvedic herb ashwagandha (Withania somnifera). J Altern Complement Med 2014; 20(12): 901-8.
[http://dx.doi.org/10.1089/acm.2014.0177] [PMID: 25405876]
[http://dx.doi.org/10.1089/acm.2014.0177] [PMID: 25405876]
[25]
Akhondzadeh S, Naghavi HR, Vazirian M, Shayeganpour A, Rashidi H, Khani M. Passionflower in the treatment of generalized anxiety: A pilot double-blind randomized controlled trial with oxazepam. J Clin Pharm Ther 2001; 26(5): 363-7.
[http://dx.doi.org/10.1046/j.1365-2710.2001.00367.x] [PMID: 11679026]
[http://dx.doi.org/10.1046/j.1365-2710.2001.00367.x] [PMID: 11679026]
[26]
Dhawan K, Kumar S, Sharma A. Anxiolytic activity of aerial and underground parts of Passiflora incarnata. Fitoterapia 2001; 72(8): 922-6.
[http://dx.doi.org/10.1016/S0367-326X(01)00322-7] [PMID: 11731118]
[http://dx.doi.org/10.1016/S0367-326X(01)00322-7] [PMID: 11731118]
[27]
Grundmann O, Wang J, McGregor G, Butterweck V. Anxiolytic activity of a phytochemically characterized Passiflora incarnata extract is mediated via the GABAergic system. Planta Med 2008; 74(15): 1769-73.
[http://dx.doi.org/10.1055/s-0028-1088322] [PMID: 19006051]
[http://dx.doi.org/10.1055/s-0028-1088322] [PMID: 19006051]
[28]
Panossian A, Wikman G, Sarris J. Rosenroot (Rhodiola rosea): Traditional use, chemical composition, pharmacology and clinical efficacy. Phytomedicine 2010; 17(7): 481-93.
[http://dx.doi.org/10.1016/j.phymed.2010.02.002] [PMID: 20378318]
[http://dx.doi.org/10.1016/j.phymed.2010.02.002] [PMID: 20378318]
[29]
Pu W, Zhang M, Bai R, et al. Anti-inflammatory effects of Rhodiola rosea L.: A review. Biomed Pharmacother 2020; 121: 109552.
[http://dx.doi.org/10.1016/j.biopha.2019.109552] [PMID: 31715370]
[http://dx.doi.org/10.1016/j.biopha.2019.109552] [PMID: 31715370]
[30]
Darbinyan V, Aslanyan G, Amroyan E, Gabrielyan E, Malmström C, Panossian A. Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nord J Psychiatry 2007; 61(5): 343-8.
[http://dx.doi.org/10.1080/08039480701643290] [PMID: 17990195]
[http://dx.doi.org/10.1080/08039480701643290] [PMID: 17990195]
[31]
Amsterdam JD, Panossian AG. Rhodiola rosea L.: As a putative botanical antidepressant. Phytomedicine 2016; 23(7): 770-83.
[http://dx.doi.org/10.1016/j.phymed.2016.02.009] [PMID: 27013349]
[http://dx.doi.org/10.1016/j.phymed.2016.02.009] [PMID: 27013349]
[32]
Chen QG, Zeng YS, Qu ZQ, et al. The effects of Rhodiola rosea extract on 5-HT level, cell proliferation and quantity of neurons at cerebral hippocampus of depressive rats. Phytomedicine 2009; 16(9): 830-8.
[http://dx.doi.org/10.1016/j.phymed.2009.03.011] [PMID: 19403286]
[http://dx.doi.org/10.1016/j.phymed.2009.03.011] [PMID: 19403286]
[33]
Butterweck V, Schmidt M. St. John’s wort: Role of active compounds for its mechanism of action and efficacy. Wien Med Wochenschr 2007; 157(13-14): 356-61.
[http://dx.doi.org/10.1007/s10354-007-0440-8] [PMID: 17704987]
[http://dx.doi.org/10.1007/s10354-007-0440-8] [PMID: 17704987]
[34]
Linde K, Berner MM, Kriston L. St John’s wort for major depression. Cochrane Database Syst Rev 2008; 2008(4): CD000448.
[http://dx.doi.org/10.1002/14651858.CD000448.pub3]
[http://dx.doi.org/10.1002/14651858.CD000448.pub3]
[35]
Savage K, Firth J, Stough C, Sarris J. GABA-modulating phytomedicines for anxiety: A systematic review of preclinical and clinical evidence. Phyther Res 2018; 32(1): 3-18.
[http://dx.doi.org/10.1002/ptr.5940]
[http://dx.doi.org/10.1002/ptr.5940]
[36]
Sarris J, Byrne GJ, Cribb L, et al. L-theanine in the adjunctive treatment of generalized anxiety disorder: A double-blind, randomised, placebo-controlled trial. J Psychiatr Res 2019; 110: 31-7.
[http://dx.doi.org/10.1016/j.jpsychires.2018.12.014] [PMID: 30580081]
[http://dx.doi.org/10.1016/j.jpsychires.2018.12.014] [PMID: 30580081]
[37]
Wang Z, Gorski J, Hamman M, Huang S, Lesko L, Hall S. The effects of St John’s wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001; 70(4): 317-26.
[http://dx.doi.org/10.1016/S0009-9236(01)17221-8] [PMID: 11673747]
[http://dx.doi.org/10.1016/S0009-9236(01)17221-8] [PMID: 11673747]
[38]
Novelli M, Masiello P, Beffy P, Menegazzi M. Protective role of St. John’s wort and its components hyperforin and hypericin against diabetes through inhibition of inflammatory signaling: Evidence from In vitro and In vivo Studies. Int J Mol Sci 2020; 21(21): 8108.
[http://dx.doi.org/10.3390/ijms21218108] [PMID: 33143088]
[http://dx.doi.org/10.3390/ijms21218108] [PMID: 33143088]
[39]
Cervo L, Rozio M, C E-S, Guiso G, Morazzoni P, Caccia S. Role of hyperforin in the antidepressant-like activity of Hypericum perforatum extracts. Psychopharmacology 2002; 164(4): 423-8.
[http://dx.doi.org/10.1007/s00213-002-1229-5] [PMID: 12457273]
[http://dx.doi.org/10.1007/s00213-002-1229-5] [PMID: 12457273]
[40]
Farooqui T, Farooqui AA, Eds. Neuroprotective effects of phytochemicals in neurological disorders. Hoboken, NJ, USA: John Wiley & Sons, Inc. 2017. Internet
[http://dx.doi.org/10.1002/9781119155195]
[http://dx.doi.org/10.1002/9781119155195]
[41]
Sukumaran NP, Amalraj A, Gopi S. Neuropharmacological and cognitive effects of Bacopa monnieri (L.) Wettst – A review on its mechanistic aspects. Complement Ther Med 2019; 44: 68-82.
[http://dx.doi.org/10.1016/j.ctim.2019.03.016] [PMID: 31126578]
[http://dx.doi.org/10.1016/j.ctim.2019.03.016] [PMID: 31126578]
[42]
Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 2009; 41(1): 40-59.
[http://dx.doi.org/10.1016/j.biocel.2008.06.010] [PMID: 18662800]
[http://dx.doi.org/10.1016/j.biocel.2008.06.010] [PMID: 18662800]
[43]
Tatsis EC, Boeren S, Exarchou V, Troganis AN, Vervoort J, Gerothanassis IP. Identification of the major constituents of Hypericum perforatum by LC/SPE/NMR and/or LC/MS. Phytochemistry 2007; 68(3): 383-93.
[http://dx.doi.org/10.1016/j.phytochem.2006.11.026] [PMID: 17196625]
[http://dx.doi.org/10.1016/j.phytochem.2006.11.026] [PMID: 17196625]
[44]
Paul S, Chakraborty S, Anand U, et al. Withania somnifera (L.) dunal (Ashwagandha): A comprehensive review on ethnopharmacology, pharmacotherapeutics, biomedicinal and toxicological aspects. Biomed Pharmacother 2021; 143: 112175.
[http://dx.doi.org/10.1016/j.biopha.2021.112175] [PMID: 34649336]
[http://dx.doi.org/10.1016/j.biopha.2021.112175] [PMID: 34649336]
[45]
Mao QQ, Xu XY, Cao SY, et al. Bioactive compounds and bioactivities of ginger (Zingiber officinale roscoe). Foods 2019; 8(6): 185.
[http://dx.doi.org/10.3390/foods8060185] [PMID: 31151279]
[http://dx.doi.org/10.3390/foods8060185] [PMID: 31151279]
[46]
Cohen AJ, Bartlik B. Ginkgo biloba for antidepressant-induced sexual dysfunction. J Sex Marital Ther 1998; 24(2): 139-43.
[http://dx.doi.org/10.1080/00926239808404927] [PMID: 9611693]
[http://dx.doi.org/10.1080/00926239808404927] [PMID: 9611693]
[47]
Mazza M, Capuano A, Bria P, Mazza S. Ginkgo biloba and donepezil: A comparison in the treatment of Alzheimer’s dementia in a randomized placebo-controlled double-blind study. Eur J Neurol 2006; 13(9): 981-5.
[http://dx.doi.org/10.1111/j.1468-1331.2006.01409.x] [PMID: 16930364]
[http://dx.doi.org/10.1111/j.1468-1331.2006.01409.x] [PMID: 16930364]
[48]
Calabrese C, Gregory WL, Leo M, Kraemer D, Bone K, Oken B. Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: A randomized, double-blind, placebo-controlled trial. J Altern Complement Med 2008; 14(6): 707-13.
[http://dx.doi.org/10.1089/acm.2008.0018] [PMID: 18611150]
[http://dx.doi.org/10.1089/acm.2008.0018] [PMID: 18611150]
[49]
Peth-Nui T, Wattanathorn J, Muchimapura S, Tong-Un T, Piyavhatkul N, Rangseekajee P, et al. Effects of 12-week bacopa monnieri consumption on attention, cognitive processing, working memory, and functions of both cholinergic and monoaminergic systems in healthy elderly volunteers. Evid Based Complement Alternat Med 2012; 2012: 606424.
[http://dx.doi.org/10.1155/2012/606424] [PMID: 23320031]
[http://dx.doi.org/10.1155/2012/606424] [PMID: 23320031]
[50]
Gupta SC, Patchva S, Koh W, Aggarwal BB. Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol 2012; 39(3): 283-99.
[http://dx.doi.org/10.1111/j.1440-1681.2011.05648.x] [PMID: 22118895]
[http://dx.doi.org/10.1111/j.1440-1681.2011.05648.x] [PMID: 22118895]
[51]
Choudhary D, Bhattacharyya S, Bose S. Efficacy and safety of ashwagandha (withania somnifera (L.) Dunal) root extract in improving memory and cognitive functions. J Diet Suppl 2017; 14(6): 599-612.
[http://dx.doi.org/10.1080/19390211.2017.1284970] [PMID: 28471731]
[http://dx.doi.org/10.1080/19390211.2017.1284970] [PMID: 28471731]
[52]
Chengappa KNR, Bowie CR, Schlicht PJ, Fleet D, Brar JS, Jindal R. Randomized placebo-controlled adjunctive study of an extract of withania somnifera for cognitive dysfunction in bipolar disorder. J Clin Psychiatry 2013; 74(11): 1076-83.
[http://dx.doi.org/10.4088/JCP.13m08413] [PMID: 24330893]
[http://dx.doi.org/10.4088/JCP.13m08413] [PMID: 24330893]
[53]
Mishra LC, Singh BB, Dagenais S. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): A review. Altern Med Rev 2000; 5(4): 334-46.
[PMID: 10956379]
[PMID: 10956379]
[54]
Aslanargun P, Cuvas O, Dikmen B, Aslan E, Yuksel MU. Passiflora incarnata Linneaus as an anxiolytic before spinal anesthesia. J Anesth 2012; 26(1): 39-44.
[http://dx.doi.org/10.1007/s00540-011-1265-6] [PMID: 22048283]
[http://dx.doi.org/10.1007/s00540-011-1265-6] [PMID: 22048283]
[55]
Krenn L. Die Passionsblume (Passiflora incarnata L.) - ein bewahrtes pflanzliches Sedativum. Wien Med Wochenschr 2002; 152(15-16): 404-6.
[http://dx.doi.org/10.1046/j.1563-258X.2002.02062.x] [PMID: 12244887]
[http://dx.doi.org/10.1046/j.1563-258X.2002.02062.x] [PMID: 12244887]
[56]
Darbinyan V, Kteyan A, Panossian A, Gabrielian E, Wikman G, Wagner H. Rhodiola rosea in stress induced fatigue — A double blind cross-over study of a standardized extract SHR-5 with a repeated low-dose regimen on the mental performance of healthy physicians during night duty. Phytomedicine 2000; 7(5): 365-71.
[http://dx.doi.org/10.1016/S0944-7113(00)80055-0] [PMID: 11081987]
[http://dx.doi.org/10.1016/S0944-7113(00)80055-0] [PMID: 11081987]
[57]
Kelly GS. Rhodiola rosea: A possible plant adaptogen. Altern Med Rev 2001; 6(3): 293-302.
[PMID: 11410073]
[PMID: 11410073]
[58]
Hunt EJ, Lester CE, Lester EA, Tackett RL. Effect of St. John’s wort on free radical production. Life Sci 2001; 69(2): 181-90.
[http://dx.doi.org/10.1016/s0024-3205(01)01102-x] [PMID: 11441908]
[http://dx.doi.org/10.1016/s0024-3205(01)01102-x] [PMID: 11441908]
[59]
Fugh-Berman A, Ernst E. Herb-drug interactions: Review and assessment of report reliability. Br J Clin Pharmacol 2001; 52(5): 587-95.
[http://dx.doi.org/10.1046/j.0306-5251.2001.01469.x] [PMID: 11736868]
[http://dx.doi.org/10.1046/j.0306-5251.2001.01469.x] [PMID: 11736868]
[60]
Srivastava S, Ahmad R, Khare SK. Alzheimer’s disease and its treatment by different approaches: A review. Eur J Med Chem 2021; 216: 113320.
[http://dx.doi.org/10.1016/j.ejmech.2021.113320] [PMID: 33652356]
[http://dx.doi.org/10.1016/j.ejmech.2021.113320] [PMID: 33652356]
[61]
Friedman JH, Brown RG, Comella C, et al. Fatigue in Parkinson’s disease: A review. Mov Disord 2007; 22(3): 297-308.
[http://dx.doi.org/10.1002/mds.21240] [PMID: 17133511]
[http://dx.doi.org/10.1002/mds.21240] [PMID: 17133511]
[62]
Scott RA, Lhatoo SD, Sander JWAS. The treatment of epilepsy in developing countries: Where do we go from here? Bull World Health Organ 2001; 79(4): 344-51.
[PMID: 11357214]
[PMID: 11357214]
[63]
Prisnie JC, Sajobi TT, Wang M, et al. Effects of depression and anxiety on quality of life in five common neurological disorders. Gen Hosp Psychiatry 2018; 52(52): 58-63.
[http://dx.doi.org/10.1016/j.genhosppsych.2018.03.009] [PMID: 29684713]
[http://dx.doi.org/10.1016/j.genhosppsych.2018.03.009] [PMID: 29684713]
[64]
Dey A, Gorai P, Mukherjee A, Dhan R, Modak BK. Ethnobiological treatments of neurological conditions in the Chota Nagpur Plateau, India. J Ethnopharmacol 2017; 198(198): 33-44.
[http://dx.doi.org/10.1016/j.jep.2016.12.040] [PMID: 28017696]
[http://dx.doi.org/10.1016/j.jep.2016.12.040] [PMID: 28017696]
[65]
Tao W, Xu X, Wang X, et al. Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal radix curcumae formula for application to cardiovascular disease. J Ethnopharmacol 2013; 145(1): 1-10.
[http://dx.doi.org/10.1016/j.jep.2012.09.051] [PMID: 23142198]
[http://dx.doi.org/10.1016/j.jep.2012.09.051] [PMID: 23142198]
[66]
Zhao C, Zhang C, Xing Z, Ahmad Z, Li JS, Chang MW. Pharmacological effects of natural ganoderma and its extracts on neurological diseases: A comprehensive review. Int J Biol Macromol 2019; 121: 1160-78.
[http://dx.doi.org/10.1016/j.ijbiomac.2018.10.076] [PMID: 30342128]
[http://dx.doi.org/10.1016/j.ijbiomac.2018.10.076] [PMID: 30342128]
[67]
Ho YS, So KF, Chang RCC. Anti-aging herbal medicine—How and why can they be used in aging-associated neurodegenerative diseases? Ageing Res Rev 2010; 9(3): 354-62.
[http://dx.doi.org/10.1016/j.arr.2009.10.001] [PMID: 19833234]
[http://dx.doi.org/10.1016/j.arr.2009.10.001] [PMID: 19833234]
